Irsamla (Vortioxetine Hydrobromide)

Irsamla, a serotonin modulator and stimulator, is used in the management of depressive disorders.

• Major depressive disorder: improves depressive symptoms and functional outcomes in adult patients.
• Persistent depressive symptoms: may be used as an adjunct when first‑line therapy is insufficient.
• Relapse prevention: helps maintain remission after acute treatment response.

• Vortioxetine inhibits the reuptake of serotonin while simultaneously modulating multiple serotonin receptors—acting as a 5‑HT1A agonist, 5‑HT1B partial agonist, and antagonizing 5‑HT3 and 5‑HT7 receptors. This combined action enhances serotonergic neurotransmission and downstream neuroplasticity, contributing to its antidepressant effects.

Vortioxetine is generally well tolerated, but a range of adverse reactions have been reported.

Common Side Effects

• Nausea: mild to moderate, often transient.
• Headache: intermittent, may resolve with continued therapy.
• Dizziness: usually mild, can be posture‑related.
• Dry mouth: reduced salivation, manageable with hydration.
• Constipation: occasional, responds to dietary fiber.
• Insomnia: difficulty initiating or maintaining sleep.

Serious or Rare Side Effects

• Serotonin syndrome: potentially life‑threatening when combined with other serotonergic agents.
• Suicidal thoughts: increased risk especially at treatment initiation.
• Severe hypertension: monitor blood pressure regularly.
• Hyponatremia: low sodium levels, particularly in elderly patients.
• Severe allergic reaction: rash, swelling, or anaphylaxis.
• QT interval prolongation: rare cardiac conduction abnormality.

Before initiating Vortioxetine therapy, clinicians should consider several safety factors.

• Assess for suicidal ideation: monitor patients closely during the first weeks of treatment.
• Avoid use with MAO inhibitors: ensure a minimum 14‑day washout period.
• Caution in hepatic impairment: dose adjustment may be required for moderate to severe liver disease.
• Monitor blood pressure: patients with pre‑existing hypertension should have regular readings.
• Pregnancy and lactation: limited data; weigh potential benefits against unknown risks.
• Store at ambient temperature: keep in the original container, protect from moisture and light.

Vortioxetine can interact with several drug classes, requiring careful management.

Major Interactions (Avoid)

• Monoamine oxidase inhibitors (MAOIs): risk of serotonin syndrome.
• Other serotonergic agents (SSRIs, SNRIs, triptans, linezolid, tramadol): may precipitate serotonin excess.
• St. John’s wort: potentiates serotonergic activity.

Moderate Interactions (Monitor Closely)

• CYP2D6 inhibitors (e.g., bupropion): may increase vortioxetine plasma levels.
• Strong CYP3A4 inhibitors (e.g., ketoconazole): may require dose adjustment.
• Alcohol: can enhance central nervous system depression.
• Antihypertensives: possible additive blood‑pressure lowering effect.
• NSAIDs: monitor for increased bleeding risk.